

**TDMS No.** 20310 - 02

**Test Type:** 26-39 WEEKS

**Route:** GAVAGE

**Species/Strain:**

MICE/C3B6F1-+/Trp53(tm1Brd)

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

3'-Azido-3'-deoxythymidine (AZT)

**CAS Number:** 30516-87-1

**Date Report Requested:** 07/22/2009

**Time Report Requested:** 11:50:52

**First Dose M/F:** 11/18/04 / NA

**Lab:** NCTR

**C Number:**

C20310C

**Lock Date:**

12/01/2008

**Cage Range:**

ALL

**Date Range:**

ALL

**Reasons For Removal:**

ALL

**Removal Date Range:**

ALL

**Treatment Groups:**

Include 612 Vehicle 6 mo M

Include 615 AZT 120 6 mo M

**Study Gender:**

Male

**TDMSE Version:**

2.1.0

---

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M
---------------------------------------	----------------	----------------

---

**Disposition Summary**

Animals Initially in Study	27	26
Early Deaths		
Moribund Sacrifice		3
Survivors		
Moribund Sacrifice		1
Natural Death		1
Terminal Sacrifice	27	21
Animals Examined Microscopically	27	26

**ALIMENTARY SYSTEM**

Gallbladder	(26)	(26)
Intestine Large, Cecum	(27)	(26)
Hyperplasia, Lymphoid	3 (11%)	1 (4%)
Intestine Small, Jejunum	(27)	(26)
Liver	(27)	(26)
Fatty Change		1 (4%)
Vacuolization Cytoplasmic	8 (30%)	4 (15%)
Pancreas	(27)	(26)
Salivary Glands	(27)	(26)
Infiltration Cellular, Lymphocyte	5 (19%)	
Stomach, Glandular	(27)	(26)

**CARDIOVASCULAR SYSTEM**

Blood Vessel	(26)	(25)
Heart	(27)	(26)
Cardiomyopathy	2 (7%)	

**ENDOCRINE SYSTEM**

Adrenal Cortex	(27)	(26)
Subcapsular, Hyperplasia	2 (7%)	2 (8%)
Thyroid Gland	(26)	(26)
Cyst		1 (4%)
Infiltration Cellular, Lymphocyte		1 (4%)

**GENERAL BODY SYSTEM**

TDMS No. 20310 - 02

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Date Report Requested: 07/22/2009

Time Report Requested: 11:50:52

First Dose M/F: 11/18/04 / NA

Lab: NCTR

---

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M
None		
<b>GENITAL SYSTEM</b>		
Epididymis	(27)	(26)
Preputial Gland	(27)	(26)
Atrophy		1 (4%)
Prostate	(27)	(26)
Inflammation, Suppurative		1 (4%)
Seminal Vesicle	(27)	(26)
Lumen, Dilatation		1 (4%)
Testes	(27)	(26)
Seminiferous Tubule, Degeneration		1 (4%)
<b>HEMATOPOIETIC SYSTEM</b>		
Bone Marrow	(27)	(26)
Myeloid Cell, Hyperplasia		1 (4%)
Lymph Node	(0)	(1)
Lymph Node, Mandibular	(26)	(26)
Hyperplasia, Lymphoid	1 (4%)	1 (4%)
Lymph Node, Mesenteric	(27)	(25)
Hyperplasia, Lymphoid	19 (70%)	16 (64%)
Hyperplasia, Plasma Cell	1 (4%)	
Spleen	(27)	(26)
Hematopoietic Cell Proliferation	1 (4%)	2 (8%)
Hyperplasia, Lymphoid	2 (7%)	
Thymus	(26)	(26)
Atrophy		1 (4%)
Hyperplasia, Lymphoid		2 (8%)
<b>INTEGUMENTARY SYSTEM</b>		
None		
<b>MUSCULOSKELETAL SYSTEM</b>		
Bone, Femur	(27)	(26)
<b>NERVOUS SYSTEM</b>		

---

a - Number of animals examined microscopically at site and number of animals with lesion

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M
Brain, Brain Stem	(27)	(26)
Brain, Cerebellum	(27)	(26)
Brain, Cerebrum	(27)	(26)
<b>RESPIRATORY SYSTEM</b>		
Lung	(27)	(26)
Abscess		1 (4%)
Nose	(27)	(26)
Inflammation, Suppurative	1 (4%)	1 (4%)
<b>SPECIAL SENSES SYSTEM</b>		
Eye	(27)	(26)
Harderian Gland	(27)	(26)
Epithelium, Hyperplasia		1 (4%)
<b>URINARY SYSTEM</b>		
Kidney	(27)	(26)
Bacterium		1 (4%)
Infiltration Cellular, Lymphocyte	7 (26%)	2 (8%)
Inflammation, Chronic Active		1 (4%)
Nephropathy		1 (4%)
Pelvis, Dilatation		2 (8%)
Transitional Epithelium, Hyperplasia	1 (4%)	1 (4%)
Urinary Bladder	(27)	(26)
Lumen, Dilatation	1 (4%)	2 (8%)

\*\*\* END OF MALE \*\*\*

\*\*\* END OF REPORT \*\*\*